$0.55 -0.02 (-3.37%) As of 06/4/2025 11:07 AM Eastern
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
